Table 2. Treatment-emergent AEs... | American Society of Hematology

Table 2.

Treatment-emergent AEs occurring in more than or equal to 15% of patients

	N = 21
	Any grade	Grade 1-2	Grade 3-4	Grade 5
Patients with an event, n (%)∗	21 (100)	4 (19.0)	13 (61.9)	4 (19.0)
Diarrhea	15 (71.4)	14 (66.7)	1 (4.8)	0
Headache	11 (52.4)	11 (52.4)	0	0
Fatigue	10 (47.6)	10 (47.6)	0	0
Neutropenia	8 (38.1)	1 (4.8)	7 (33.3)	0
COVID-19	7 (33.3)	1 (4.8)	2 (9.5)	4 (19.0)†
Dizziness	7 (33.3)	7 (33.3)	0	0
Cough	6 (28.6)	6 (28.6)	0	0
Paresthesia	6 (28.6)	6 (28.6)	0	0
Dyspnea	5 (23.8)	4 (19.0)	1 (4.8)	0
Hypoesthesia	5 (23.8)	5 (23.8)	0	0
Myalgia	5 (23.8)	5 (23.8)	0	0
Memory impairment	4 (19.0)	4 (19.0)	0	0
Peripheral edema	4 (19.0)	3 (14.3)	1 (4.8)	0
Pruritus	4 (19.0)	4 (19.0)	0	0
Upper respiratory tract infection	4 (19.0)	4 (19.0)	0	0
Blurred vision	4 (19.0)	4 (19.0)	0	0

	N = 21
	Any grade	Grade 1-2	Grade 3-4	Grade 5
Patients with an event, n (%)∗	21 (100)	4 (19.0)	13 (61.9)	4 (19.0)
Diarrhea	15 (71.4)	14 (66.7)	1 (4.8)	0
Headache	11 (52.4)	11 (52.4)	0	0
Fatigue	10 (47.6)	10 (47.6)	0	0
Neutropenia	8 (38.1)	1 (4.8)	7 (33.3)	0
COVID-19	7 (33.3)	1 (4.8)	2 (9.5)	4 (19.0)†
Dizziness	7 (33.3)	7 (33.3)	0	0
Cough	6 (28.6)	6 (28.6)	0	0
Paresthesia	6 (28.6)	6 (28.6)	0	0
Dyspnea	5 (23.8)	4 (19.0)	1 (4.8)	0
Hypoesthesia	5 (23.8)	5 (23.8)	0	0
Myalgia	5 (23.8)	5 (23.8)	0	0
Memory impairment	4 (19.0)	4 (19.0)	0	0
Peripheral edema	4 (19.0)	3 (14.3)	1 (4.8)	0
Pruritus	4 (19.0)	4 (19.0)	0	0
Upper respiratory tract infection	4 (19.0)	4 (19.0)	0	0
Blurred vision	4 (19.0)	4 (19.0)	0	0

Regardless of causality assessment.

A patient with multiple severity grades for a given AE is counted only once under the maximum severity.

A fifth patient died from COVID-19 infection outside the treatment-emergent period (30 days after discontinuation of all study drugs).